Cipher Pharmaceuticals Inc banner

Cipher Pharmaceuticals Inc
OTC:CPHRF

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
OTC:CPHRF
Watchlist
Price: 11.64 USD -0.51% Market Closed
Market Cap: $299.1m

Wall St Price Targets

CPHRF Price Targets Summary
Cipher Pharmaceuticals Inc

Wall Street analysts forecast CPHRF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CPHRF is 14.48 USD with a low forecast of 12.3 USD and a high forecast of 16.55 USD.

Lowest Forecast
Price Target
12.3 USD
6% Upside
Average Forecast
Price Target
14.48 USD
24% Upside
Highest Forecast
Price Target
16.55 USD
42% Upside
Cipher Pharmaceuticals Inc Competitors:
Price Targets
FIZZ
National Beverage Corp
8% Upside

Revenue
Forecast

15% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
15% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 12%.

Gross Profit
Forecast

N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
20% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate for Gross Profit over the next 3 years is 20%.

Operating Income
Forecast

16% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat
16% / Year
Past Growth
31% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat

Over the last 13 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 1 year is 31%.

Pre-Tax Income
Forecast

16% / Year
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
16% / Year
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 32%.

Net Income
Forecast

20% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
31%
Average Beat
20% / Year
Past Growth
16% / Year
Estimated Growth
Estimates Accuracy
31%
Average Beat

Over the last 13 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 16%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is CPHRF's stock price target?
Price Target
14.48 USD

According to Wall Street analysts, the average 1-year price target for CPHRF is 14.48 USD with a low forecast of 12.3 USD and a high forecast of 16.55 USD.

What is the Revenue forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
12%

Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 12%.

What is the Gross Profit forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
20%

The compound annual growth rate for Gross Profit over the next 3 years is 20%.

What is the Operating Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
31%

Over the last 13 years, the compound annual growth rate for Operating Income has been 16%. The projected CAGR for the next 1 year is 31%.

What is the Pre-Tax Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
32%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 16%. The projected CAGR for the next 3 years is 32%.

What is the Net Income forecast for Cipher Pharmaceuticals Inc?
Projected CAGR
16%

Over the last 13 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 16%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett